Zusammenfassung
Präparationen hämatopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmöglichkeiten und Zukunftsperspektiven. Sie sind die Basis für Stammzelltransplantationen, d.h. für die Wiederherstellung der Hämatopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten. Weiterhin könnten sie in der Zukunft ein Transportvehikel für die Gentherapie darstellen. Stammzellen können vom Knochenmark, vom peripheren Blut oder aus Nabelschnurblut gewonnen werden. Der vorliegende Artikel vermittelt einen Überblick über die Biologie der Stammzellen über, Verfahren ihrer Gewinnung, die gesetzliche Grundlage für die Herstellung von Stammzellpräparationen sowie über die Grundzüge der Anforderungen für deren Zulassung. Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel, wenn sie nicht für eine bestimmte erkrankte Person hergestellt werden, sondern im voraus produziert und — bis zu ihrem Gebrauch — in sogenannten Zellbanken gelagert werden.
Summary
In principle, haematopoietic stem cell preparations offer a paramount array of clinical opportunities and future perspectives. They are the basis for stem cell transplantation, e.g. for rescue of haematopoiesis after high dose cytotoxic therapy, for treatment of immunologic deficiencies and congenital metabolic disorders, and, in the future, a vehicle for gene therapy. Stem cells may be obtained from bone marrow, peripheral blood, or umbilical cord blood. This article provides an overview of the biology of stem cells, procedures for their collection, the legal basis for the manufacture of stem cell preparations, and essential requirements for their marketing authorisation. According to German legislation, stem cell preparations are medicinal products necessitating a marketing authorisation, if they are not produced for a certain ill person, but manufactured beforehand and banked until needed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Metcalf D, Moore MAS (1971) Haemotopoietic cells. Amsterdam: North Holland, pp 362–447.
Dexter TM, Coutinho LH, Spooncer E, et al. (1990) Stromal cells in hemopoiesis. In: Bock G, March J (eds) Molecular control of hemopoiesis. Wiley and Sons, Sussex, UK, pp 76–86.
Abramson S, Miller RG, Philips RA (1997) The identification in adult marrow of pluripotent and restricted stem cells of the myeloid and lymphoid systems. J Exp Med 145: 1567–1579.
Philips R (1991) Hematopoietic stem cells: concepts, assays, and controversies. Sem Immunol 3:337–347.
Morrison S, Uchida N, Weissman I (1995) The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol 11:35–71.
Thomas ED (1982) The role of marrow transplantation in the eradication of malignant disease. Cancer 49:1963–1969.
Bortin MM, Horowitz MM, Rimm AA (1992) Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988–1990 survey. Ann Intern Med 116: 505–512.
Thomas ED (1991) Frontiers in bone marrow transplantation. Blood Cells 17:259–267.
Marmont AM (1993) New frontiers for allogeneic bone marrow transplantation. Bone Marrow Transplant 11:3–10.
Übersicht in: Lu L, Shen RN, Broxmeyer HE (1996) Stem cells from bone marrow, umbilical cord blood and peripheral blood for clinical application: current status and future application. Critical Reviews in: Oncology/Hematology 22:61–78.
Baumann I, Testa NG, Lange C, et al. (1993) Haemopoietic cells mobilised into the circulation by lenograstim as alternative to bone marrow for allogeneic transplants. Lancet 341:369–372.
Williams SF, Bitran JD, Richards JM, et al. (1990) Peripheral blood-derived stem cell collections for use in autologous transplantation after high dose chemotherapy: an alternative approach. Bone Marrow Transplant 5:129–133.
Kotasek D, Shepherd KM, Sage RE, et al. (1992) Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 9:11–17.
Sheridan WP, Begley CG, Juttner CA, et al. (1992) Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640–644.
Kanz L, Brugger W, Mertelsmann R (1992) Mobilization of peripheral blood progenitor cells by hemopoietic growth factors following standard dose chemotherapy. Bone Marrow Transplant 10:6–10.
Kritz A, Crown JP, Motzer RJ, et al. (1993) Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial. Cancer 71:2515–2521.
Teshima T, Inaba S, Harada M, et al. (1992) Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant 10:215–220.
Übersicht in: Gale RP, Henon P, Juttner C (1992) Blood stem cell transplants come of age. Bone Marrow Transplant 9:151–155.
Chao NJ, Schriber JR, Grimes K, et al. (1993) Granulocyte colony-stimulating factor „mobilized“peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81:2031–2033.
Broxmeyer HE, Douglas DW, Hangoc G, et al. (1989) Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 86:3838–3832.
Gluckman E, Broxmeyer HE, Auerbach A, et al. (1989) Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 321:1174–1178.
Wagner JE, Kernan NA, Steinbach M, et al. (1995) Allogeneic sibling cord blood transplantation in forty-four children with malignant and non-malignant disease. Lancet 346:214–219.
Kurtzberg J, Laughlin M, Graham ML, et al. (1996) Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. New Engl J Med 335:157–166.
Broxmeyer HE, Hangoc G, Cooper S (1992) Clinical and biological aspects of human umbilical cord blood as a source of transplantable hematopoietic stem and progenitor cells. Bone Marrow Transpl 9:7–10.
Wagner JE, Rosenthal J, Sweetman R, et al. (1995) Successful transplantation of HLA-matched and HLO-mismatched umbilical cord blood from unrelated donors: anlaysis of engraftment and acute graft-versus-host disease. Blood 88:795–802.
Gluckmann E, Rocha V, Boyer-Chammard A, et al. (1997) Outcome of cord blood transplantation from related and unrelated donors. New Engl J Med 337:373–381.
Broxmeyer HE, Hangoc G, Cooper S, et al. (1992) Growth charcteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci USA 89:4109–4113.
Hows JM, Bradley BA, Marsh JCW, et al. (1992) Growth of human umbilical cord blood in long-term haemopoietic cultures. Lancet 340:73–76.
Stiehm ER, Sztein MB, Steeg PS, et al. (1984) Deficient DR antigen expression on human cord blood monocytes: reversal with lymphokines. Clin Immunol Immunopathol 30:430–436.
Taylor S, Bryson YJ (1985) Impaired production of %-interferon by newborn cells in vitro is due to functionally immature macrophage. J Immunol 134:1493–1497.
Anderson U, Bird AG, Britton S, et al. (1981) Humoral and cellular immunity in human studied at the cell level from birth to two years of age. Immunol Rev 57:5–38.
Foa R, Giubellino MC, Fierro MT, et al. (1984) Immature T lymphocytes in human cord blood identified by monoclonal antibodies: a model for the study of the differentiation pathway of T cells in humans. Cell Immunol 89:194–201.
Gabbianelli M, Broccoli G, Cianetti L, et al. (1990) HLA expression in hematopoietic development. Class I and II antigens are induced in the definitive erythroid lineage and differentially modulated by fet al liver cytokines. J Immunol 144:3354–3360.
Gale RP (1992) Fet al liver transplants. Bone Marrow Transplant 9:118–120.
Touraine JL, Roncarlo MG, Royo C, et al. (1987) Fet al tissue transplantation, bone marrow transplantation and prospective gene therapy in severe immunodeficiencies and enzyme deficiencies. Thymus 10:75–87.
Gluckman E, Devergie A, Thierry D, et al. (1992) Clinical applications of stem cell transfusion from cord blood and rationale for cord blood banking. Bone Marrow Transplant 9: 114–117.
Gluckman E, Wagner J, Hows J et al. (1993) Cord blood banking for hematopoietic stem cell transplantation: an international cord blood transplant registry. Bone Marrow Transplant 11:199–200.
Rubinstein R, Rosenfield RE, Adamson JW, et al. (1993) Stored placental blood for unrelated bone marrow reconstitution. Blood 81: 1679–1690.
Silberstein LE, Jefferles LC (1996) Placentalblood banking — a new frontier in transfusion medicine. N Engl J Med 335:199–201.
Krause DS, Fackler MJ, Civin CI, et al. (1996) CD34: structure, biology, and clinical utility. Blood 87:1–13.
Andrews R, Singer J, Bernstein I (1989) Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of CD33 and CD34 antigen by light scatter. J Exp Med 169:1721.
Jones RJ, et al. (1996) Characterization of mouse lymphohematopoietic stem cells lacking spleen colony-forming activity. Blood 88:487–491.
Goodell MA, Brose K, Paradis G, et al. (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183:1797–1806.
Osawa M, Hanada K, Hamada H, et al. (1996) Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. Science 273: 242–245.
Zanjani ED, Almeida-Porada G, Livingston AG, et al. (1998) Human bone marrow CD34-negative cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34-positive cells. Exp Hematol 26:353–360.
Bhatia M, Bonnet D, Murdoch B, et al. (1998) A newly discovered class of human hematopoetic cells with SCID-repopulating activity. Nature Medicine 4:1038–1047.
Williams DA (1993) Ex vivo expansion of hematopoietic stem and progenitor cells — Robbing Peter to pay Paul? Blood 81: 3169–3172.
Ruggieri L, Heimfeld S, Broxmeyer HE (1994) Cytokine-dependent ex-vivo expansion of early subsets of CD34 cord blood myeloid progenitors is greatly enhanced by cord blood plasma, but expansion of the more mature subsets of progenitors is favored. Blood Cells 20:436–454.
Xiao M, Broxmeyer HE, Horie M, et al. (1994) Extensive proliferative capacity of single isolated CD34 human cord blood cells in suspension culture. Blood Cells 20:455–467.
Williams DA (1990) Expression of introduced genetic sequences in hematopoietic cells following retroviral-mediated gene transfer. Hum Gen Therap 1:229–239.
Karlsson S (1991) Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood 78:2481–2492.
Al-Lebban ZS, Henry JM, Jones JB, et al. (1990) Increased efficiency of gene transfer with retroviral vectors in neonatal hematopoietic progenitor cells. Exp Hematol 18: 180–186.
Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz). BgBI. IS. 2445 vom 24. August 1976 in der geltenden Fassung.
Gesetz zur Regelung des Transfusionswesens (Transfusionsgesetz — TFG). BGBI. IS. 1752 vom 6Juli 1998.
Betriebsverordnung für pharmazeutische Unternehmer (PharmBetrV). BgBI. IS. 546 vom 8. März 1985 in der geltenden Fassung.
Recommendation No R (95) 15 on the preparation, use and quality assurance of blood components. Council of Europe, 5. Ausgabe, 1998.
Empfehlung des Rates über die Eignung von Blut-und Plasmaspendern und das Screening von Blutspenden in der Europäischen Gemeinschaft. Amtsblatt der Europäischen Gemeinschaften, L203, S. 14-26 vom 21.7.1998.
Kommission der Europäischen Gemeinschaften (1990) Leitfaden einer guten Herstellungspraxis für Arzneimittel, mit ergänzenden Leitlinien. In: Die Regelung der Arzneimittel in der Europäischen Gemeinschaft, Band IV, Amt für amtliche Veröffentlichungen der Europäischen Gemeinschaften.
Richtlinie der Kommission zur Festlegung der Grundsätze und Leitlinien der Guten Herstellungspraxis (GMP) für zur Anwendung beim Menschen bestimmten Arzneimittel. (91/356/WEWG) vom 13.06.1991.
Richtlinien zur Blutgruppenbestimmung und Bluttransfusion (Hämotherapie). Aufgestellt vom Wissenschaftlichen Beirat der Bundesärztekammer und vom Paul-Ehrlich-In-stitut. Bundesgesundhbl 1996; 39:468-489.
Richtlinien für die allogene Knochenmarktransplantation mit nichtverwandten Spendern. Aufgestellt vom Wissenschaftlichen Beirat der Bundesärztekammer. Dt Ärztebl 1994;91:A761-766.
Richtlinien zur Transplantation peripherer Blutstammzellen. Aufgestellt vom Wissenschaftlichen Beirat der Bundesärztekammer unter Mitwirkung des Paul-Ehrlich-Institutes. Dt Ärztebl 1997; 94: A1584-1592.
Richtlinien zur Transplantation von Stammzellen aus Nabelschnurblut (CB=Cord Blood). Aufgestellt vom Wissenschaftlichen Beirat der Bundesärztekammer und vom Paul-Ehrlich-Institut (in Vorbereitung).
Richtlinien zum Gentransfer in menschliche Körperzellen. Richtlinien des ständigen Arbeitskreises „Biomedizinische Ethik und Technologiefolgenabschätzung“ beim Wissenschaftlichen Beirat der Bundesärztekammer. Dt Ärztebl 1995; 92: B583-588.
Proposed approach to regulation of cellular and tissue-based products. Docket No. 97N-0068,28.02.1997.
Guidance for human somatic cell therapy and gene therapy. März 1998.
Mittl.98/C229/03 der Kommission des Europäischen Rates.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Huber, H.M., Heiden, M., Seitz, R. (1999). Hämatopoetische Stammzellen. In: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-38283-7_21
Download citation
DOI: https://doi.org/10.1007/978-3-662-38283-7_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-37515-0
Online ISBN: 978-3-662-38283-7
eBook Packages: Springer Book Archive